Boston Scientific (NYSE:BSX) Updates FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.340-3.410 for the period, compared to the consensus earnings per share estimate of 3.450. The company issued revenue guidance of $21.5 billion-$21.8 billion, compared to the consensus revenue estimate of $22.2 billion. Boston Scientific also updated its Q2 2026 guidance to 0.820-0.840 EPS.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $4.99 during mid-day trading on Wednesday, hitting $64.51. The company had a trading volume of 7,597,011 shares, compared to its average volume of 15,634,536. The stock has a market cap of $95.88 billion, a price-to-earnings ratio of 33.37, a PEG ratio of 0.94 and a beta of 0.78. Boston Scientific has a 12 month low of $59.38 and a 12 month high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm’s 50 day simple moving average is $69.04 and its two-hundred day simple moving average is $86.31.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific will post 3.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of analyst reports. The Goldman Sachs Group reduced their price target on Boston Scientific from $98.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Oppenheimer reduced their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. JPMorgan Chase & Co. reduced their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Citigroup dropped their price objective on Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $115.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $101.50.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.34% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results showed durable topline growth and a small EPS beat: net sales of $5.203B (up ~11.6% year/year) and adjusted EPS $0.80, slightly above consensus; GAAP net income rose sharply year over year — a signal that demand for core devices remains solid. Boston Scientific announces results for first quarter 2026
• Neutral Sentiment: Several sell‑side firms have adjusted models/price targets but many still rate BSX a Buy — analysts view the guidance cut as a potential reset that creates longer‑term upside if execution rebounds. Boston Scientific Stock Is Trending Today: What To Know Now
• Neutral Sentiment: Unusually high options activity (large call purchases) and elevated trading volume ahead of the print indicate traders positioned for volatility rather than a clear directional conviction; this can amplify intraday moves.
• Negative Sentiment: Management cut FY‑2026 and Q2 guidance: FY EPS guide of $3.340–3.410 vs. ~3.45 consensus and Q2 EPS guide of $0.820–0.840 vs. ~0.86 consensus; revenue outlook was lowered as well — the guidance miss/trim is the primary near‑term negative catalyst. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple securities class‑action filings and investor‑notice campaigns (several law firms seeking lead plaintiffs; May 4 deadline) add headline/legal risk and can pressure sentiment and float until resolved. BSX Investor Alert: Securities Fraud Lawsuit
• Negative Sentiment: Recent reports of meaningful insider and institutional selling, plus prior analyst downgrades/target trims, increase near‑term supply pressure and reduce confidence until management demonstrates rehabbed guidance/trajectory.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. grew its holdings in Boston Scientific by 33.0% during the fourth quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider’s stock valued at $135,000 after purchasing an additional 350 shares during the last quarter. Compound Planning Inc. raised its holdings in Boston Scientific by 14.7% in the 4th quarter. Compound Planning Inc. now owns 15,423 shares of the medical equipment provider’s stock worth $1,471,000 after acquiring an additional 1,978 shares during the period. Axxcess Wealth Management LLC lifted its position in Boston Scientific by 130.9% during the 4th quarter. Axxcess Wealth Management LLC now owns 28,347 shares of the medical equipment provider’s stock worth $2,703,000 after acquiring an additional 16,068 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Boston Scientific by 11.1% during the fourth quarter. Corient Private Wealth LLC now owns 242,992 shares of the medical equipment provider’s stock valued at $22,238,000 after acquiring an additional 24,194 shares during the period. Finally, Strive Financial Group LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $1,499,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.